Published in Lancet Oncol on October 02, 2009
Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res (2010) 2.33
Challenges translating breast cancer gene signatures into the clinic. Nat Rev Clin Oncol (2011) 1.86
Tumor size and survival in breast cancer--a reappraisal. Nat Rev Clin Oncol (2010) 1.70
Biomarkers in Breast Cancer - An Update. Geburtshilfe Frauenheilkd (2012) 1.41
Breast cancer assessment tools and optimizing adjuvant therapy. Nat Rev Clin Oncol (2010) 1.32
Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction. Breast Cancer Res (2011) 1.30
Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon? EPMA J (2013) 1.17
PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer (2012) 1.13
Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study. Br J Cancer (2013) 1.09
Molecular profiling currently offers no more than tumour morphology and basic immunohistochemistry. Breast Cancer Res (2010) 1.05
A simple decision analytic solution to the comparison of two binary diagnostic tests. Stat Med (2012) 0.98
Progress in adjuvant chemotherapy for breast cancer: an overview. BMC Med (2015) 0.93
External validation of Adjuvant! Online breast cancer prognosis tool. Prioritising recommendations for improvement. PLoS One (2011) 0.89
Accuracy validation of adjuvant! online in Taiwanese breast cancer patients--a 10-year analysis. BMC Med Inform Decis Mak (2012) 0.88
Derivation of cancer diagnostic and prognostic signatures from gene expression data. Bioanalysis (2010) 0.86
Comparison of Nottingham Prognostic Index and Adjuvant Online prognostic tools in young women with breast cancer: review of a single-institution experience. BMJ Open (2015) 0.85
Telomere fusion threshold identifies a poor prognostic subset of breast cancer patients. Mol Oncol (2015) 0.83
Validity of the online PREDICT tool in older patients with breast cancer: a population-based study. Br J Cancer (2016) 0.80
A multichannel Markov random field framework for tumor segmentation with an application to classification of gene expression-based breast cancer recurrence risk. IEEE Trans Med Imaging (2012) 0.80
Underestimated survival predictions of the prognostic tools Adjuvant! Online and PREDICT in BRCA1-associated breast cancer patients. Fam Cancer (2013) 0.79
Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study. PLoS One (2016) 0.77
The predictive accuracy of PREDICT: a personalized decision-making tool for Southeast Asian women with breast cancer. Medicine (Baltimore) (2015) 0.77
Gene expression profiling in breast cancer. Am J Transl Res (2013) 0.77
The Performance of the Nottingham Prognosis Index and the Adjuvant Online Decision Making Tool for Prognosis in Early-stage Breast Cancer Patients. Int J Prev Med (2015) 0.76
Prediction of breast cancer survival using clinical and genetic markers by tumor subtypes. PLoS One (2015) 0.75
Adjuvant! When the new world meets the old world. Lancet Oncol (2009) 0.75
Modern Risk Assessment for Individualizing Treatment Concepts in Early-stage Breast Cancer. Rev Obstet Gynecol (2013) 0.75
Validation of the CancerMath prognostic tool for breast cancer in Southeast Asia. BMC Cancer (2016) 0.75
Effect of PREDICT on chemotherapy/trastuzumab recommendations in HER2-positive patients with early-stage breast cancer. Oncol Lett (2014) 0.75
Prognostic models in male breast cancer. Breast Cancer Res Treat (2016) 0.75
Agreement on indication for systemic therapy between biopsied tissue and surgical excision specimens in breast cancer patients. PLoS One (2014) 0.75
Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models. Br J Cancer (2015) 0.75
The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients. Br J Cancer (2016) 0.75
Preoperative indication for systemic therapy extended to patients with early-stage breast cancer using multiparametric 7-tesla breast MRI. PLoS One (2017) 0.75
Early health technology assessment of magnetic resonance-guided high intensity focused ultrasound ablation for the treatment of early-stage breast cancer. J Ther Ultrasound (2017) 0.75
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
Concordance among gene-expression-based predictors for breast cancer. N Engl J Med (2006) 13.50
Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A (2005) 10.85
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet (2007) 7.35
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist (2009) 6.00
Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol (2010) 5.25
Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med (2009) 4.80
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci U S A (2003) 4.47
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol (2008) 4.42
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol (2005) 4.31
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol (2009) 4.05
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat (2011) 3.63
Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancer. J Clin Oncol (2008) 3.44
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol (2007) 3.32
Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood (2010) 3.21
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res (2003) 3.02
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat (2011) 2.73
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72
Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol (2010) 2.46
Modeling precision treatment of breast cancer. Genome Biol (2013) 2.42
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet (2013) 2.24
A protocol for building and evaluating predictors of disease state based on microarray data. Bioinformatics (2005) 2.08
Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation. J Natl Cancer Inst (2003) 2.02
The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat (2008) 1.96
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet (2013) 1.88
The clinical epidemiology of urachal carcinoma: results of a large, population based study. J Urol (2012) 1.88
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res (2012) 1.81
A decision aid to assist in adjuvant therapy choices for breast cancer. Psychooncology (2006) 1.80
The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. Eur J Cancer (2011) 1.79
Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol (2008) 1.76
The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis. Hum Mol Genet (2010) 1.73
Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol (2005) 1.73
Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma. N Engl J Med (2015) 1.70
Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Res (2005) 1.70
Common breast cancer susceptibility loci are associated with triple-negative breast cancer. Cancer Res (2011) 1.65
Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. Cancer Res (2002) 1.64
The validity of the mortality to incidence ratio as a proxy for site-specific cancer survival. Eur J Public Health (2010) 1.62
Survival after treatment for carcinoma invading bladder muscle: a Dutch population-based study on the impact of hospital volume. BJU Int (2011) 1.60
Treatment of stage I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgery. Radiother Oncol (2011) 1.60
Association of ESR1 gene tagging SNPs with breast cancer risk. Hum Mol Genet (2009) 1.58
A comparison of univariate and multivariate gene selection techniques for classification of cancer datasets. BMC Bioinformatics (2006) 1.57
Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 1.56
Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood (2004) 1.56
Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. PLoS Genet (2013) 1.56
One naive T cell, multiple fates in CD8+ T cell differentiation. J Exp Med (2010) 1.55
Decreased use of adjuvant breast cancer therapy in a randomized controlled trial of a decision aid with individualized risk information. Med Decis Making (2005) 1.51
Prostate-sparing cystectomy: long-term oncological results. BJU Int (2009) 1.51
Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol (2007) 1.50
Annexin A1 regulates TGF-beta signaling and promotes metastasis formation of basal-like breast cancer cells. Proc Natl Acad Sci U S A (2010) 1.42
Oral and oropharyngeal cancer in The Netherlands between 1989 and 2006: Increasing incidence, but not in young adults. Oral Oncol (2009) 1.41
Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. Am J Hum Genet (2013) 1.39
The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet (2006) 1.32
Pleural mesothelioma incidence in Europe: evidence of some deceleration in the increasing trends. Cancer Causes Control (2003) 1.32
Leukemia and brain tumors among children after radiation exposure from CT scans: design and methodological opportunities of the Dutch Pediatric CT Study. Eur J Epidemiol (2014) 1.30
Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev (2009) 1.29
CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. J Clin Oncol (2012) 1.29
Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genet Med (2005) 1.27
11q13 is a susceptibility locus for hormone receptor positive breast cancer. Hum Mutat (2012) 1.26
Independent prognostic value of screen detection in invasive breast cancer. J Natl Cancer Inst (2011) 1.23
Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.23
The role of genetic breast cancer susceptibility variants as prognostic factors. Hum Mol Genet (2012) 1.23
Preventing neural tube defects in Europe: a missed opportunity. Reprod Toxicol (2005) 1.22
Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989. Eur J Cancer (2010) 1.21
Does delay in diagnosing colorectal cancer in symptomatic patients affect tumor stage and survival? A population-based observational study. BMC Cancer (2010) 1.20
Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers. Breast Cancer Res Treat (2004) 1.19
Pulmonary squamous cell carcinoma following head and neck squamous cell carcinoma: metastasis or second primary? Clin Cancer Res (2005) 1.17
ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer. PLoS Biol (2012) 1.16
Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). PLoS One (2012) 1.13
Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls. Cancer Epidemiol Biomarkers Prev (2009) 1.13
Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study. Breast Cancer Res (2007) 1.12
Cervical cancer in the Netherlands 1989-1998: Decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. Int J Cancer (2005) 1.11
The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat (2007) 1.10
A role for XRCC2 gene polymorphisms in breast cancer risk and survival. J Med Genet (2011) 1.10
Survey of informed consent for registration of congenital anomalies in Europe. BMJ (2005) 1.09
The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients. Breast Cancer Res (2011) 1.07
Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry. Eur J Cancer (2013) 1.05
Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients. Clin Cancer Res (2009) 1.05
Sustained lower rates of breast cancer in the United States. Breast Cancer Res Treat (2008) 1.05
Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies. Curr Drug Saf (2013) 1.05
Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation. Int J Cancer (2009) 1.04
Evaluation of Cladribine treatment in refractory celiac disease type II. World J Gastroenterol (2011) 1.04
Implementation of a novel microarray-based diagnostic test for cancer of unknown primary. Int J Cancer (2009) 1.03
The spectrum of ATM missense variants and their contribution to contralateral breast cancer. Breast Cancer Res Treat (2007) 1.03